IDEXX Acquires CoVetAI to Push AI Workflow Into Vet Clinics
The diagnostics giant is buying an ambient AI scribe for veterinarians, betting that software is the next battleground in animal health.
By Good Company Editorial Desk
By Good Company Editorial Desk | September 29, 2026
The News
IDEXX Laboratories announced on September 16, 2026 that it has acquired CoVetAI Inc., a provider of AI-native ambient listening and clinical workflow software for veterinary practices. CoVet's software automatically captures and organizes patient information from consultation through treatment planning and client follow-up, reducing the documentation burden on clinical teams.
CoVet will be integrated into IDEXX's software ecosystem. The company said CoVet will continue to support third-party integrations and veterinary practices that do not use IDEXX practice management systems. Deal terms were not disclosed. IDEXX is headquartered in Westbrook, Maine, and its chief executive is Mike Erickson.
Why It Matters
Veterinary medicine has a documentation problem. Vets spend hours each day on medical records, and burnout linked to administrative load is one of the profession's most persistent complaints. Ambient AI scribes, already spreading through human healthcare, promise to take that load off by listening to consultations and drafting the record automatically. IDEXX buying CoVet is the clearest signal yet that the biggest company in veterinary diagnostics sees clinical workflow software as strategically essential, not just a nice add-on.
The acquisition logic is straightforward. IDEXX already owns the diagnostic data flowing through clinics; adding the workflow layer means it can connect test results, clinical notes, and treatment plans in one system. That makes IDEXX's ecosystem stickier for practices and gives it a platform to sell more software services over time. For independent AI scribe startups, the deal both validates the category and raises the competitive bar considerably.
The Numbers
IDEXX trades on Nasdaq under the ticker IDXX and is the largest pure-play animal health diagnostics company in the world, which makes any acquisition it does newsworthy by definition. CoVet serves both corporate veterinary groups and independent practices worldwide, though neither company disclosed customer counts or revenue figures. The purchase price was not disclosed.
The commitment to keep supporting non-IDEXX practice management systems is the strategically interesting detail. It suggests IDEXX wants CoVet to keep growing across the whole market rather than using it solely as a lock-in tool, at least for now. That openness will be tested over time.
What To Watch
Integration is the first test. IDEXX has a strong record of folding acquisitions into its commercial machine, but software workflow products live or die on user experience, and heavy-handed integration could alienate the practices that made CoVet attractive. Second, watch the competitive response: the remaining independent veterinary AI scribe companies now face a much better-funded rival, and partnership or acquisition activity in the space is likely to accelerate. Third, watch for the product roadmap. If IDEXX starts connecting CoVet's ambient notes directly with its diagnostic results and treatment recommendations, the company will have built something its competitors cannot easily replicate.